No description
-
2013 (v1)PublicationUploaded on: March 27, 2023
-
2016 (v1)Publication
Four HCC characteristics typically inform tumor behavior: maximum tumor size, number of nodules, portal vein thrombosis and serum AFP level. The sum of these parameters was recently published as an HCC Aggressiveness Index. We aimed to validate this index retrospectively in a larger and independent HCC cohort of 2706 Italian HCC patients, and...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
Background & Aims: Significant proportion of Hepatocellular Carcinoma (HCC) cases are diagnosed in stage B of Barcelona Clinic Liver Cancer (BCLC) algorithm, in which the standard of care is Transcatheter Arterial ChemoEmbolization (TACE). We aimed to ascertain adherence to current guidelines, survival and prognostic factors in BCLC stage B...
Uploaded on: April 14, 2023 -
2012 (v1)Publication
Alpha-fetoprotein is a tumor marker that has been used for surveillance and diagnosis of hepatocellular carcinoma (HCC) in patients with cirrhosis. The prognostic capability of this marker in patients with HCC has not been clearly defined. In this study our aim was to evaluate the prognostic usefulness of serum alpha-fetoprotein in patients...
Uploaded on: March 27, 2023 -
2010 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2017 (v1)Publication
Background & Aims: The Barcelona Clinic Liver Cancer intermediate stage (BCLC-B) of hepatocellular carcinoma (HCC) includes extremely heterogeneous patients in terms of tumour burden and liver function. Transarterial-chemoembolization (TACE) is the first-line treatment for these patients although it may be risky/useless for someone, while...
Uploaded on: March 27, 2023 -
2014 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2016 (v1)Publication
Background Prognostic assessment in patients with hepatocellular carcinoma (HCC) remains controversial. Using the Italian Liver Cancer (ITA.LI.CA) database as a training set, we sought to develop and validate a new prognostic system for patients with HCC. Methods and Findings Prospective collected databases from Italy (training cohort, n =...
Uploaded on: April 14, 2023 -
2016 (v1)Publication
OBJECTIVES: The Barcelona Clinic Liver Cancer (BCLC) intermediate stage (BCLC B) includes a heterogeneous population of patients with hepatocellular carcinoma (HCC). Recently, in order to facilitate treatment decisions, a panel of experts proposed to subclassify BCLC B patients. In this study, we aimed to assess the prognostic capability of the...
Uploaded on: April 14, 2023 -
2015 (v1)Publication
No description
Uploaded on: March 27, 2023 -
2015 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
No description
Uploaded on: April 14, 2023 -
2016 (v1)Publication
Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved.
Uploaded on: April 14, 2023